News >

Lenalidomide Maintenance Post-ASCT Improves Survival in Myeloma

Jason Harris
Published: Friday, Oct 13, 2017

Philip L. McCarthy, MD

Philip L. McCarthy, MD
Maintenance therapy with lenalidomide (Revlimid) following autologous stem-cell transplantation (ASCT) conferred a survival benefit for patients with newly diagnosed multiple myeloma, according to results from a meta-analysis published in the Journal of Clinical Oncology.1

Compared with patients assigned to placebo or observation (n = 603), those assigned to lenalidomide (n = 605) had superior progression-free survival (PFS; 52.8 vs 23.5 months), with a hazard ratio (HR) of 0.48 (95% CI, 0.41-0.55). Median follow-up was 79.5 months for all surviving patients at the March 1, 2015 data cutoff. At that time, median overall survival (OS) was 86.0 months for the placebo or observation group and had not been reached for the lenalidomide maintenance group (HR, 0.75; 95% CI, 0.63-0.90; P = .001).
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication
x